Cardiomyocytes derived from human induced pluripotent stem cells (iPSCs) show great promise as autologous donor cells to treat heart disease. A major technical obstacle to this approach is that available induction methods often produce heterogeneous cell population with low percentage of cardiomyocytes. Here we describe a cardiac enrichment approach using nonintegrating adeno-associated virus (AAV). We first examined several AAV serotypes for their ability to selectively transduce iPSC-derived cardiomyocytes. Results showed that AAV1 demonstrated the highest in vitro transduction efficiency among seven widely used serotypes. Next, differentiated iPSC derivatives were transduced with drug-selectable AAV1 expressing neomycin resistance gene. Selection with G418 enriched the cardiac cell fraction from 27% to 57% in 2 weeks. Compared with other enrichment strategies such as integrative genetic selection, mitochondria labeling, or surface marker cell sorting, this simple AAV method described herein bypasses antibody or dye labeling. These findings provide proof of concept for large-scale cardiomyocyte enrichment by exploiting AAV's intrinsic tissue tropism.
Get full access to this article
View all access options for this article.
References
1.
GinnSL, AlexanderIE, EdelsteinML, et al.Gene therapy clinical trials worldwide to 2012—an update. J Gene Med, 2013; 15:65–77.
2.
Penaud-BudlooM, Le GuinerC, NowrouziA, et al.Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol, 2008; 82:7875–7885.
3.
NowrouziA, Penaud-BudlooM, KaeppelC, et al.Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther, 2012; 20:1177–1186.
4.
EllisBL, HirschML, BarkerJC, et al.A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol J, 2013; 10:74.
5.
RaptiK, StillitanoF, KarakikesI, et al.Effectiveness of gene delivery systems for pluripotent and differentiated cells. Mol Ther Methods Clin Dev, 2015; 2; 14067.
6.
GuanX, MackDL, MorenoCM, et al.Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery. Stem Cell Res, 2014; 12:467–480.
7.
LianX, HsiaoC, WilsonG, et al.Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci USA, 2012; 109:E1848–E1857.
AsokanA, SchafferDV, SamulskiRJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther, 2012; 20:699–708.
10.
ZseboK, YaroshinskyA, RudyJJ, et al.Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res, 2014; 114:101–108.
11.
WangZ, ChamberlainJS, TapscottSJ, StorbR. Gene therapy in large animal models of muscular dystrophy. ILAR J, 2009; 50:187–198.
12.
ShibaY, FernandesS, ZhuWZ, et al.Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature, 2012; 489:322–325.
SekineH, ShimizuT, DobashiI, et al.Cardiac cell sheet transplantation improves damaged heart function via superior cell survival in comparison with dissociated cell injection. Tissue Eng Part A, 2011; 17:2973–2980.
15.
XueT, ChoHC, AkarFG, et al.Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. Circulation, 2005; 111:11–20.
16.
PlotnikovAN, ShlapakovaI, SzabolcsMJ, et al.Xenografted adult human mesenchymal stem cells provide a platform for sustained biological pacemaker function in canine heart. Circulation, 2007; 116:706–713.
17.
ShintaniS, KusanoK, IiM, et al.Synergistic effect of combined intramyocardial CD34+ cells and VEGF2 gene therapy after MI. Nat Clin Practice Cardiovasc Med, 2006; 3Suppl 1:S123–S128.
18.
ZhangM, MethotD, PoppaV, et al.Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol, 2001; 33:907–921.
19.
CaoF, LinS, XieX, et al.In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation, 2006; 113:1005–1014.
20.
ZacchignaS, ZentilinL, GiaccaM. Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system. Circ Res, 2014; 114:1827–1846.
21.
LovricJ, ManoM, ZentilinL, et al.Terminal differentiation of cardiac and skeletal myocytes induces permissivity to AAV transduction by relieving inhibition imposed by DNA damage response proteins. Mol Ther, 2012; 20:2087–2097.
22.
KattmanSJ, HuberTL, KellerGM. Multipotent flk-1+cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. Dev Cell, 2006; 11:723–732.
23.
ZhangJ, KlosM, WilsonGF, et al.Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res, 2012; 111:1125–1136.
HattoriF, ChenH, YamashitaH, et al.Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Meth, 2010; 7:61–66.
26.
TohyamaS, HattoriF, SanoM, et al.Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell, 2012; 12:127–137.
27.
Nguyen DoanC, Hookway TracyA, WuQ, et al.Microscale generation of cardiospheres promotes robust enrichment of cardiomyocytes derived from human pluripotent stem cells. Stem Cell Rep, 2014; 3:260–268.
28.
KattmanSJ, WittyAD, GagliardiM, et al.Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell, 2011; 8:228–240.
29.
UosakiH, FukushimaH, TakeuchiA, et al.Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PLoS One, 2011; 6:e23657.
30.
Van HoofD, DormeyerW, BraamSR, et al.Identification of cell surface proteins for antibody-based selection of human embryonic stem cell-derived cardiomyocytes. J Proteome Res, 2010; 9:1610–1618.
HuserD, Gogol-DoringA, ChenW, HeilbronnR. Adeno-associated virus type 2 wild-type and vector-mediated genomic integration profiles of human diploid fibroblasts analyzed by third-generation PacBio DNA sequencing. J Virol, 2014; 88:11253–11263.
33.
JanovitzT, KleinIA, OliveiraT, et al.High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration. J Virol, 2013; 87:8559–8568.
34.
RosasLE, GrievesJL, ZaraspeK, et al.Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. Mol Ther, 2012; 20:2098–2110.
35.
GauttierV, PichardV, AubertD, et al.No tumour-initiating risk associated with scAAV transduction in newborn rat liver. Gene Ther, 2013; 20:779–784.
36.
WerfelS, JungmannA, LehmannL, et al.Rapid and highly efficient inducible cardiac gene knockout in adult mice using AAV-mediated expression of Cre recombinase. Cardiovasc Res, 2014; 104:15–23.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
